Value of surgery in patients with negative imaging and sporadic zollinger-ellison syndrome

Annals of Surgery

Volumn 256, Issue 3, 2012, Pages 509-517

  Norton, Jeffrey A ^a   Fraker, Douglas L ^b   Alexander, H Richard ^c   Jensen, Robert T ^d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

gastrinoma; negative imaging; outcome; surgery

Indexed keywords

GASTRIN; PENTETATE INDIUM IN 111; SOMATOSTATIN RECEPTOR;

ADULT; CANCER SURVIVAL; CONFERENCE PAPER; DEATH; DUODENUM; FEMALE; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; HUMAN; IMAGING; LIVER METASTASIS; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PANCREAS; PHLEBITIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; THERAPY DELAY; TREATMENT OUTCOME; TUMOR VOLUME; ZOLLINGER ELLISON SYNDROME;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GASTRINOMA; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROSPECTIVE STUDIES; SPLENECTOMY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT; ZOLLINGER-ELLISON SYNDROME;

EID: 84865445592     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318265f08d     Document Type: Conference Paper

References (44)

1. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep. 2004;6:454-463. (Pubitemid 39591825)
2. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119.
3. Ellison EC, Sparks J. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors? Am J Surg. 2003;186:245-248. (Pubitemid 38368623)
4. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228-238. (Pubitemid 30191719)
5. Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg. 2004;239:617-625; discussion 626.
6. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635-644. (Pubitemid 29399042)
7. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615-630. (Pubitemid 29075250)
8. McCarthy DM. The place of surgery in the Zollinger-Ellison syndrome. N Engl J Med. 1980;302:1344-1347. (Pubitemid 10117726)
9. McNamara D, Lewis T, O'Moran C. Zollinger-Ellison syndrome with fasting hypoglycaemia. J R Soc Med. 1998;91:92-93. (Pubitemid 28075911)
10. Hirschowitz BI. Surgery to cure the Zollinger-Ellison syndrome. N Engl JMed. 1999;341:2096-2097.
11. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3:39-48. (Pubitemid 40092942)
12. Wilcox CM, Seay T, Arcury JT, et al. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. Dig Liver Dis. 2011;43:439-443.
13. Collins JS, Buchanan KD,Kennedy TL, et al.Changing patterns in presentation andmanagement of the Zollinger-Ellison syndrome in Northern Ireland, 1970-1988. Q J Med. 1991;78:215-225.
14. Quatrini M, Castoldi L, Rossi G, et al. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol. 2005;39:376-380. (Pubitemid 40548073)
15. Hung PD, Schubert ML, Mihas AA. Zollinger-Ellison syndrome. Curr Treat Options Gastroenterol. 2003;6:163-170.
16. Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther. 2001;15:1555-1561. (Pubitemid 32912397)
17. Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410-419.
18. Fraker DL, Norton JA, Alexander HR, et al. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320-328; discussion 328-330.
19. Krampitz GW, Norton JA, Poultsides GA, et al. Lymph nodes and survival in duodenal and pancreatic neuroendocrine tumors. Arch Surg. 2012. In press.
20. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000;79:379-411.
21. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome, part I: prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295-330. (Pubitemid 44772671)
22. Krudy AG, Doppman JL, Jensen RT, et al. Localization of islet cell tumors by dynamic CT: comparison with plain CT, arteriography, sonography, and venous sampling. AJR Am J Roentgenol. 1984;143:585-589. (Pubitemid 14067875)
23. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997;112:335-347. (Pubitemid 27078820)
24. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539-553. (Pubitemid 29171794)
25. Norton JA, Alexander HR, Chen Y, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724-732.
26. Cherner JA, Doppman JL, Norton JA, et al. Selective venous sampling for gastrin to localize gastrinomas. A prospective assessment. Ann Intern Med. 1986;105:841-847. (Pubitemid 17201757)
27. Doppman JL. Pancreatic endocrine tumors-the search goes on. N Engl JMed. 1992;326:1770-1772.
28. Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intra-arterial injection of secretin. Radiology. 1990;174:25-29. (Pubitemid 20017077)
29. Norton JA, Jensen RT. Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg. 2007;205:S34-S37. (Pubitemid 47488912)
30. Fraker DL,Norton JA, Saeed ZA, et al.Aprospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery. 1988;104:1054-1063. (Pubitemid 19011986)
31. Norton JA, Cromack DT, Shawker TH, et al. Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Ann Surg. 1988;207:160-168. (Pubitemid 18063597)
32. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg. 1992;215:8-18.
33. Fishbeyn VA, Norton JA, Benya RV, et al. Assessment and prediction of longterm cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199-206. (Pubitemid 23327619)
34. Norton JA, Alexander HR, Fraker DL, et al. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg. 2003;237:650-657; discussion 657-659.
35. Zollinger RM, Ellison EC, Fabri PJ, et al. Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five year appraisal. Ann Surg. 1980;192:422-430. (Pubitemid 10048289)
36. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773. (Pubitemid 39425767)
37. Howard TJ, Zinner MJ, Stabile BE, et al. Gastrinoma excision for cure. A prospective analysis. Ann Surg. 1990;211:9-14. (Pubitemid 20027876)
38. Stabile BE, Passaro E Jr. Benign and malignant gastrinoma. Am J Surg. 1985;149:144-150. (Pubitemid 15156170)
39. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637-1649.
40. Norton JA, Jensen RT. Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome. World J Surg. 1991;15:151-159.
41. Thom AK, Norton JA, Axiotis CA, et al. Location, incidence, and malignant potential of duodenal gastrinomas. Surgery. 1991;110:1086-1091; discussion 1091-1083.
42. Sugg SL, Norton JA, Fraker DL, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993;218:138-144. (Pubitemid 23229139)
43. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg. 1993;17:455-462. (Pubitemid 23228398)
44. Thom AK, Norton JA, Doppman JL, et al. Prospective study of the use of intra-arterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery. 1992;112:1002-1008; discussion 1008-1009.